Trials / Completed
CompletedNCT00490178
Acceptability Study of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Type 2 Diabetes and Dyslipidemia
An Open Label, Multicenter Trial Assessing the Acceptability of a New Fixed Combination of Fenofibrate 80 mg BID and Metformin 1000 mg BID in Patients With Type 2 Diabetes and Dyslipidemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The present study aims to assess the acceptability of a 4 week treatment of a new fixed-dose combination of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fenofibrate 80 mg and metformin 1000 mg (fixed combination) |
Timeline
- Start date
- 2007-03-01
- First posted
- 2007-06-22
- Last updated
- 2007-09-03
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00490178. Inclusion in this directory is not an endorsement.